84P Metastatic mismatch repair deficiency cancers: Hard to find, but a delight to treat!

Metastatic cancers with mismatch repair (MMR) deficiency, seen especially in cancers of the uterus and gastrointestinal tract, are rare and seen in about 5% of patients. They show very good and durable response to treatment with immunotherapy, leading to a tumor agnostic approval in this indication. There is very limited data of MMR deficient patients treated with immunotherapy from India.